{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:07:32Z","timestamp":1786993652394,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005756","name":"Shahrekord University of Medical Sciences","doi-asserted-by":"publisher","award":["2904"],"award-info":[{"award-number":["2904"]}],"id":[{"id":"10.13039\/501100005756","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.lfs.2021.119027","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T01:54:55Z","timestamp":1610589295000},"page":"119027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Apoptotic effects of valproic acid on miR-34a, miR-520h and HDAC1 gene in breast cancer"],"prefix":"10.1016","volume":"269","author":[{"given":"Nastaran","family":"Injinari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Amini-Farsani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahtab","family":"Yadollahi-Farsani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Teimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2021.119027_bb0005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3389\/fonc.2018.00227","article-title":"Recent advances in the treatment of breast cancer","volume":"8","author":"Tong","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2021.119027_bb0010","first-page":"1","article-title":"Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials","volume":"4","author":"Cheng","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.lfs.2021.119027_bb0015","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.bbamcr.2010.06.013","article-title":"MicroRNAs: synthesis, mechanism, function, and recent clinical trials","volume":"1803","author":"Wahid","year":"2010","journal-title":"Biochim. Biophys. Acta - Mol. Cell Res."},{"key":"10.1016\/j.lfs.2021.119027_bb0020","first-page":"2735","article-title":"MicroRNAs and cancer: key paradigms in molecular therapy","volume":"15","author":"Tan","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.lfs.2021.119027_bb0025","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1158\/0008-5472.CAN-16-0359","article-title":"OncomiR or tumor suppressor? The duplicity of MicroRNAs in cancer","volume":"76","author":"Svoronos","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2021.119027_bb0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ebiom.2016.09.017","article-title":"microRNA therapeutics in cancer - an emerging concept","volume":"12","author":"Shah","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.lfs.2021.119027_bb0035","doi-asserted-by":"crossref","first-page":"e1327","DOI":"10.1038\/cddis.2014.270","article-title":"MicroRNA-34a: a potential therapeutic target in human cancer","volume":"5","author":"Li","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.lfs.2021.119027_bb0040","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.molcel.2007.05.010","article-title":"Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis","volume":"26","author":"Chang","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.lfs.2021.119027_bb0045","doi-asserted-by":"crossref","first-page":"13421","DOI":"10.1073\/pnas.0801613105","article-title":"miR-34a repression of SIRT1 regulates apoptosis","volume":"105","author":"Yamakuchi","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2021.119027_bb0050","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.canlet.2014.08.031","article-title":"MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer","volume":"354","author":"Wu","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.lfs.2021.119027_bb0055","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/onc.2015.168","article-title":"miR-520h is crucial for DAPK2 regulation and breast cancer progression","volume":"35","author":"Su","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.lfs.2021.119027_bb0060","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/onc.2012.74","article-title":"MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol","volume":"32","author":"Yu","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.lfs.2021.119027_bb0065","article-title":"The activation of microRNA-520h\u2013associated TGF-\u03b21\/c-Myb\/Smad7 axis promotes epithelial ovarian cancer progression","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.lfs.2021.119027_bb0070","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.bjc.6605724","article-title":"hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations","volume":"103","author":"Wang","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lfs.2021.119027_bb0075","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.febslet.2013.11.034","article-title":"Downregulation of histone deacetylase 1 by microRNA-520h contributes to the chemotherapeutic effect of doxorubicin","volume":"588","author":"Shen","year":"2014","journal-title":"FEBS Lett."},{"key":"10.1016\/j.lfs.2021.119027_bb0080","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/jcb.20179","article-title":"Regulation of histone deacetylase activities","volume":"93","author":"Sengupta","year":"2004","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.lfs.2021.119027_bb0085","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/hepr.12757","article-title":"Histone deacetylases function as novel potential therapeutic targets for cancer","volume":"47","author":"Zhang","year":"2017","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.lfs.2021.119027_bb0090","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cca.2018.05.005","article-title":"Prognostic and clinical significance of histone deacetylase 1 expression in breast cancer: a meta-analysis","volume":"483","author":"Qiao","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.lfs.2021.119027_bb0095","article-title":"Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer","volume":"96","author":"Cao","year":"2017","journal-title":"Med. (United States)."},{"key":"10.1016\/j.lfs.2021.119027_bb0100","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1128\/MCB.00494-07","article-title":"Role for histone deacetylase 1 in human tumor cell proliferation","volume":"27","author":"Senese","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.lfs.2021.119027_bb0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.21873\/anticanres.11286","article-title":"Histone deacetylase inhibitors: an attractive therapeutic strategy against breast cancer","volume":"37","author":"Damaskos","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lfs.2021.119027_bb0110","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2021.119027_bb0115","first-page":"1","article-title":"Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials","volume":"4","author":"Cheng","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.lfs.2021.119027_bb0120","series-title":"Anti-Convulsant Drug Valproic Acid in Cancers and in Combination Anti-cancer Therapeutics","author":"Sun","year":"2014"},{"key":"10.1016\/j.lfs.2021.119027_bb0125","series-title":"Effect of Valproic Acid on Cisplatin-resistant Ovarian Cancer Cell Lines","first-page":"39","volume":"21","author":"Somayeh","year":"2019"},{"key":"10.1016\/j.lfs.2021.119027_bb0130","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.neulet.2017.08.018","article-title":"Valproic acid exposure decreases the mRNA stability of Bcl-2 via up-regulating miR-34a in the cerebellum of rat","volume":"657","author":"Dai","year":"2017","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.lfs.2021.119027_bb0135","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/s12010-017-2684-0","article-title":"Valproic acid promotes apoptosis and cisplatin sensitivity through downregulation of H19 noncoding RNA in ovarian A2780 cells","volume":"185","author":"Sajadpoor","year":"2018","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.lfs.2021.119027_bb0140","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-019-1160-9","article-title":"Valproic acid exhibits anti-tumor activity selectively against EGFR\/ErbB2\/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs","volume":"38","author":"Lin","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2021.119027_bb0145","first-page":"1","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.lfs.2021.119027_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep20518","article-title":"Discovering gene re-ranking efficiency and conserved gene-gene relationships derived from gene co-expression network analysis on breast cancer data","volume":"6","author":"Bourdakou","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2021.119027_bb0155","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1158\/0008-5472.CAN-16-2717","article-title":"Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer","volume":"77","author":"Cejalvo","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2021.119027_bb0160","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/bcr27","article-title":"Gene therapy for carcinoma of the breast pro-apoptotic gene therapy","volume":"2","author":"G\u00f3mez-Navarro","year":"2000","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.lfs.2021.119027_bb0165","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/150845","article-title":"Apoptosis and molecular targeting therapy in cancer","volume":"2014","author":"Hassan","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.lfs.2021.119027_bb0170","series-title":"Cell Death - Autophagy, Apoptosis Necrosis","article-title":"Apoptotic molecular advances in breast cancer management","author":"Moela","year":"2015"},{"key":"10.1016\/j.lfs.2021.119027_bb0175","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/978-1-61779-012-6_9","article-title":"Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability","volume":"716","author":"Sylvester","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.lfs.2021.119027_bb0180","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/jcb.27512","article-title":"Genipin induces cell death via intrinsic apoptosis pathways in human glioblastoma cells","volume":"120","author":"Ahani","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.lfs.2021.119027_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173509","article-title":"The effect of oleuropein on apoptotic pathway regulators in breast cancer cells","author":"Asgharzade","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119027_bb0190","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.lfs.2021.119027_bb0195","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-019-0776-0","article-title":"The timeline of epigenetic drug discovery: from reality to dreams","volume":"11","author":"Ganesan","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.lfs.2021.119027_bb0200","doi-asserted-by":"crossref","first-page":"106270","DOI":"10.18632\/oncotarget.22286","article-title":"miR-34a expression in human breast cancer is associated with drug resistance","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.lfs.2021.119027_bb0205","first-page":"109","article-title":"MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1","volume":"132","author":"Li","year":"2012","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.lfs.2021.119027_bb0210","first-page":"1","article-title":"The activation of microRNA-520h\u2013associated TGF-\u03b21\/c-Myb\/Smad7 axis promotes epithelial ovarian cancer progression","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.lfs.2021.119027_bb0215","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.bjc.6605724","article-title":"Hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations","volume":"103","author":"Wang","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2021.119027_bb0220","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5301\/tj.5000224","article-title":"Analysis of MicroRNA expression profile identifies novel biomarkers for non-small cell lung cancer","volume":"101","author":"Xu","year":"2015","journal-title":"Tumori"},{"key":"10.1016\/j.lfs.2021.119027_bb0225","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cbi.2017.12.003","article-title":"Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells","volume":"280","author":"Aztopal","year":"2018","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.lfs.2021.119027_bb0230","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","article-title":"ROS in cancer therapy: the bright side of the moon","volume":"52","author":"Perillo","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.lfs.2021.119027_bb0235","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/931251","article-title":"Evidence in support of potential applications of lipid peroxidation products in cancer treatment","volume":"2013","author":"Erejuwa","year":"2013","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.lfs.2021.119027_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117403","article-title":"Regulation of PD-L1 expression on cancer cells with ROS-modulating drugs","volume":"246","author":"Bailly","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2021.119027_bb0245","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-13-63","article-title":"Rac3 induces a molecular pathway triggering breast cancer cell aggressiveness: differences in MDA-MB-231 and MCF-7 breast cancer cell lines","volume":"13","author":"Gest","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lfs.2021.119027_bb0250","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41586-018-0409-3","article-title":"Genetic and transcriptional evolution alters cancer cell line drug response","volume":"560","author":"Ben-David","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119027_bb0255","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2889","article-title":"Choosing the right cell line for breast cancer research","volume":"13","author":"Holliday","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.lfs.2021.119027_bb0260","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2007.10.006","article-title":"Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells","volume":"259","author":"Fortunati","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.lfs.2021.119027_bb0265","first-page":"1","article-title":"Metabolomics reveals the effect of valproic acid on MCF-7 and MDA-MB-231 cells","author":"Zhou","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1016\/j.lfs.2021.119027_bb0270","first-page":"20466","article-title":"Valproic acid (VPA) suppresses the expression of SMAD4 in prostate carcinoma by up-regulating miR-34a","volume":"9","author":"Xia","year":"2016","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.lfs.2021.119027_bb0275","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejphar.2008.04.058","article-title":"Clinically relevant concentrations of valproic acid modulate melatonin MT1 receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells","volume":"589","author":"Kim","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119027_bb0280","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1128\/MCB.23.19.6993-7004.2003","article-title":"Autoregulation of mouse histone deacetylase 1 expression","volume":"23","author":"Schuettengruber","year":"2003","journal-title":"Mol. Cell. Biol."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521000126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521000126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T17:48:25Z","timestamp":1772732905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320521000126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":56,"alternative-id":["S0024320521000126"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119027","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apoptotic effects of valproic acid on miR-34a, miR-520h and HDAC1 gene in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"119027"}}